髓系KIF13B通过抑制STT3A/CTSD/THBS1轴防止MASH
该研究探讨髓系巨噬细胞中KIF13B在MASLD/MASH中的作用。发现MASLD条件下单核细胞来源巨噬细胞KIF13B表达显著下调,髓系Kif13b缺失使小鼠易患饮食诱导的MASLD;机制上KIF13B通过促进STT3A蛋白酶体降解抑制CTSD糖基化分泌,进而减少肝细胞脂质堆积和炎症。
要点
- MASLD条件下巨噬细胞KIF13B表达显著下调,髓系缺失促进饮食诱导MASLD。
- KIF13B缺失 impair STT3A蛋白酶体降解,增强CTSD糖基化与分泌。
- CTSD通过结合肝细胞膜蛋白THBS1发挥促脂质堆积和炎症效应。
核心结论
- 研究确立ZNF384/KIF13B/STT3A/CTSD/THBS1轴在MASLD进展中巨噬细胞-肝细胞对话的关键作用,并提供潜在治疗靶点。
研究设计与样本
- 研究在MASLD条件下检测单核细胞来源巨噬细胞KIF13B表达,并使用髓系Kif13b缺失小鼠评估饮食诱导MASLD。
主要发现
- MASLD条件下单核细胞来源巨噬细胞KIF13B表达显著下调,髓系Kif13b缺失使小鼠易患饮食诱导的MASLD。
- Kif13b缺失损害巨噬细胞中STT3A的蛋白酶体依赖性降解,增强CTSD糖基化和分泌,促进肝脏脂质蓄积和炎症反应。
- CTSD的有害效应依赖其与肝细胞膜蛋白THBS1的相互作用。
- 转录因子ZNF384通过直接结合KIF13B基因启动子激活其转录,ZNF384在MASLD中表达也显著下调。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a critical pathological stage that can progress to liver fibrosis and hepatocellular carcinoma, and its development is closely associated with dysregulation of the hepatic immune microenvironment, in which macrophages make a crucial contribution. However, the precise mechanisms mediated by macrophages underlying the pathogenesis of this disease remain incompletely understood. APPROACH AND RESULTS: In the present study, we demonstrate that under MASLD conditions, KIF13B expression is markedly downregulated in monocyte-derived macrophages, and deletion of myeloid-derived Kif13b predisposes mice to diet-induced MASLD. Mechanistically, Kif13b deficiency impairs proteasome-dependent degradation of the glycosyltransferase STT3A in macrophages, thereby enhancing cathepsin D (CTSD) glycosylation and secretion to promote lipid accumulation and inflammatory responses in livers. Further analyses reveal that the detrimental effects of CTSD depend on its interaction with the hepatocyte membrane protein Thrombospondin 1 (THBS1). In addition, we identify the transcription factor ZNF384 as a potential upstream regulator of KIF13B gene through directly binding to its promoter for the transcriptional activation, which expression is also significantly downregulated in the context of MASLD. CONCLUSIONS: Collectively, our study establishes a novel regulatory axis, ZNF384/KIF13B/STT3A/CTSD/THBS1, essential for macrophage-hepatocyte crosstalk during MASLD progression and provides potential therapeutic targets for the treatment of MASLD.
引用
- Lu K, Shen X, Guo Z, et al. Myeloid KIF13B suppresses the STT3A/CTSD/THBS1 axis to prevent MASH. Hepatology. 2026. PMID: 41746601. doi:10.1097/HEP.0000000000001726
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。